ICON has the relationships already built up with companies doing Alzheimer's clinical trials. It is worth it for AMBS to align themselves with a company like that in order to accelerate the penetration of this market. Shareholders should be happy about that. Lympro should also grow the number of clinical trials with an easy to use blood test and both ICON and AMBS knows this. Shareholders should be happy with that. We can attach any name we want to the 'deal'. It was the best strategy.